Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications

被引:25
作者
Hillegass, WB [1 ]
Brott, BC [1 ]
Chapman, GD [1 ]
Phillips, HR [1 ]
Stack, RS [1 ]
Tcheng, JE [1 ]
Califf, RM [1 ]
机构
[1] Univ Alabama, Birmingham, AL 35294 USA
关键词
D O I
10.1067/mhj.2002.123143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Approximately 50% of percutaneous coronary interventions in the United States are performed with unfractionated heparin and no Ilb/IIIa agent. The operator must weigh the risks and benefits of. more intensive anticoagulation during these percutaneous interventions. This study helps clarify the relationship between patient and procedural factors, such as the intensity of heparin anticoagulation as measured by activated clotting time (ACT), and the risk of blood loss and bleeding complications. Methods Four hundred twenty-nine patients undergoing elective or urgent percutaneous coronary intervention were followed up prospectively for 72 hours after intervention for clinical bleeding complications. Blood loss, defined as the difference between preprocedural and nadir postprocedural hematocrit adjusted for interval transfusions, was also tracked. In-laboratory ACTs, as well as other potential clinical and procedural predictors of blood loss and bleeding risk, were collected and analyzed. Results Maximum in-laboratory ACT was significantly related to blood loss as measured by the change in hematocrit (P = .017) and to the risk of major bleeding complications (P = .002). In multivariate analysis, patient age (P = .004), sex (P = .014), procedure length (P < .001), and additional interventions (P < .001) were significant, independent predictors of blood loss. Major bleeding complications were significantly, independently predicted by patient age (P < .001), additional interventions (P = .015), and maximum in-laboratory ACT (P < .001). Conclusions Compared with the other clinical and procedural predictors of bleeding complications, maximum inlaboratory ACT was second only to patient age in significance as a multivariate predictor of postprocedural bleeding complications. Maximum in-laboratory ACT was found to be the most significant modifiable univariate and multivariate predictor of clinical bleeding complications after percutaneous coronary intervention. Particularly in patients with nonmodifiable risk factors for blood loss and bleeding complications such as advanced age, female sex, and multiple and prolonged procedures, avoiding high intensity anticoagulation with unfractionated heparin is associated with lower bleeding risk.
引用
收藏
页码:501 / 507
页数:7
相关论文
共 25 条
[1]   BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].
AGUIRRE, FV ;
TOPOL, EJ ;
FERGUSON, JJ ;
ANDERSON, K ;
BLANKENSHIP, JC ;
HEUSER, RR ;
SIGMON, K ;
TAYLOR, M ;
GOTTLIEB, R ;
HANOVICH, G ;
ROSENBERG, M ;
DONOHUE, TJ ;
WEISMAN, HF ;
CALIFF, RM .
CIRCULATION, 1995, 91 (12) :2882-2890
[2]   COMPARISON OF HEMOCHRON AND HEMOTEC ACTIVATED COAGULATION TIME TARGET VALUES DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [J].
AVENDANO, A ;
FERGUSON, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (04) :907-910
[3]   Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial [J].
Blankenship, JC ;
Hellkamp, AS ;
Aguirre, FV ;
Demko, SL ;
Topol, EJ ;
Califf, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (01) :36-40
[4]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[5]  
Chew DP, 2001, CIRCULATION, V103, P961
[6]  
CLOYD GM, 1987, J THORAC CARDIOV SUR, V94, P535
[7]  
COX DR, 1958, J R STAT SOC B, V20, P215
[8]  
ESPOSITO RA, 1983, J THORAC CARDIOV SUR, V85, P346
[9]   RELATION BETWEEN PROCEDURAL ACTIVATED COAGULATION TIME AND OUTCOME AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [J].
FERGUSON, JJ ;
DOUGHERTY, KG ;
GAOS, CM ;
BUSH, HS ;
MARSH, KC ;
LEACHMAN, DR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :1061-1065
[10]   IMPORTANCE OF ADEQUATE HEPARIN DOSAGE IN ARTERIAL ANGIOPLASTY IN A PORCINE MODEL [J].
HERAS, M ;
CHESEBRO, JH ;
PENNY, WJ ;
BAILEY, KR ;
LAM, JYT ;
HOLMES, DR ;
REEDER, GS ;
BADIMON, L ;
FUSTER, V .
CIRCULATION, 1988, 78 (03) :654-660